Michael Gelband’s UroGen Pharma URGN Stock Holding History

Michael Gelband’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-70,240	Closed	-$1.26M	–	2097
2026 Q1	$1.26M	Buy	70,240 +34,847	+98%	+$699K	0.01%	928
2025 Q4	$829K	Buy	35,393 +18,850	+114%	+$409K	0.01%	1061
2025 Q3	$330K	Buy	+16,543	New	+$297K	﹤0.01%	1284
2025 Q1	–	Sell	-33,598	Closed	-$358K	–	2024
2024 Q4	$358K	Buy	+33,598	New	+$402K	﹤0.01%	1232
2019 Q2	–	Sell	-12,208	Closed	-$451K	–	1341
2019 Q1	$451K	Buy	+12,208	New	+$512K	0.03%	359

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Michael Gelband's URGN Position: Q2 2026 in Review

Michael Gelband sold out of UroGen Pharma (URGN) in Q2 2026, closing a stake of 70,240 shares — an estimated $1.26M sold.

Michael Gelband first reported a position in URGN in Q1 2019 and held it in 5 quarters. The position peaked at $1.26M in Q1 2026. 188 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Michael Gelband reported no remaining UroGen Pharma position as of Q2 2026 after selling out during the quarter.
Michael Gelband sold 70,240 UroGen Pharma shares in Q2 2026, an estimated $1.26M.
Michael Gelband first reported a position in UroGen Pharma in Q1 2019 and held it in 5 quarters.
Michael Gelband's UroGen Pharma position peaked at $1.26M in Q1 2026.
188 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.